Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Voya Investment Management LLC

Key Points

• Voya Investment Management LLC has reduced its stake in Ultragenyx Pharmaceutical Inc. by 12.6%, selling 9,125 shares and holding a total of 63,196 shares valued at approximately $2.29 million.
• Recent trading has shown significant activity, with other hedge funds like GAMMA Investing LLC increasing their stake by 76.2%, and institutional investors now owning 97.67% of the company's stock.
• Ultragenyx reported a revenue increase of 13.2% year-over-year, totaling $166.5 million, and beat earnings estimates by $0.10 with an EPS of ($1.17).

Voya Investment Management LLC decreased its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 12.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 63,196 shares of the biopharmaceutical company's stock after selling 9,125 shares during the period. Voya Investment Management LLC owned about 0.07% of Ultragenyx Pharmaceutical worth $2,288,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in RARE. GAMMA Investing LLC boosted its position in Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares in the last quarter. ANTIPODES PARTNERS Ltd purchased a new position in Ultragenyx Pharmaceutical during the first quarter valued at approximately $57,000. Headlands Technologies LLC purchased a new position in Ultragenyx Pharmaceutical during the first quarter valued at approximately $59,000. Covestor Ltd increased its position in shares of Ultragenyx Pharmaceutical by 86.8% in the first quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company's stock valued at $62,000 after buying an additional 795 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $82,000. Institutional investors own 97.67% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on RARE shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $105.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Canaccord Genuity Group reduced their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Guggenheim reissued a "buy" rating and issued a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Morgan Stanley reduced their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday, July 14th. Finally, Wells Fargo & Company cut their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a report on Thursday, July 10th. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $81.50.

Insiders Place Their Bets

In other news, EVP Karah Herdman Parschauer sold 2,450 shares of the company's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the sale, the executive vice president directly owned 73,271 shares in the company, valued at $2,283,857.07. This represents a 3.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 5.50% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock traded up $1.34 during mid-day trading on Monday, hitting $29.47. 1,600,317 shares of the company were exchanged, compared to its average volume of 1,508,165. The business's 50 day simple moving average is $28.98 and its two-hundred day simple moving average is $33.86. The company has a market capitalization of $2.84 billion, a P/E ratio of -5.33 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a 12-month low of $25.81 and a 12-month high of $59.50.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, topping the consensus estimate of ($1.27) by $0.10. The company had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.Ultragenyx Pharmaceutical's revenue was up 13.2% compared to the same quarter last year. During the same quarter last year, the business posted ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.